Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917142 | 0.89 | CTSS (0.55) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL4917131 | 0.89 | CTSS (0.55) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL4922943 | 0.84 | CTSS (0.60) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL4922934 | 0.84 | CTSS (0.60) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL7029037 | 0.84 | CTSS (0.60) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL26999158 | 0.83 | ATM (0.64) | CTSSCTSKATMLMNAMAPT | |
| SCHEMBL4915481 | 0.83 | CTSS (0.53) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL4915478 | 0.83 | CTSS (0.53) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL4915475 | 0.83 | CTSS (0.53) | CTSSCTSKPTPN1SCN9AATM | |
| SCHEMBL17015 | 0.82 | CTSS (0.60) | CTSSCTSKPTPN1SCN9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1702916-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-09-20 | — | — | EP | disclosed |
| EP-1702916-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | CTSS 271/4885CTSK 124/4885PTPN1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.